Amgen (AMGN, $185.98) Makes Anti-Cholestrol Drug More Affordable, via a -60% Price Cut
Amgen Inc. is slashing prices of its cholesterol fighting drug Repatha, amidst rising healthcare costs and increased regulatory surveillance to protect patients from exorbitant medicine prices.
The biopharmaceutical company will reduce the U.S. list price of Repatha by -60% - from more than $14,000 a year to $5,850. Repatha is one of the injectable medications that aim to mitigate high cholesterol problems and lower chances of heart attack and stroke. Higher prices have reportedly been hurting demand for such drugs, thereby potentially posing concerns about people’s health. In Q2, revenue from Repatha was $148 million – which beat estimates, was still much lower compared to analysts' previously high expectations about its success. Amgen’s price cut decision also comes amidst U.S. President Donald Trump’s administration’s initiatives to increase transparency on drugs’ pricing and to ease financial constraints faced by U.S. patients.
Talking about its drug price reduction, Murdo Gordon, Amgen’s new executive vice president of global commercial operations said, “The impact we’re trying to have is on high-risk patients, and about 65 percent of those are on a Medicare plan” .
AMGN sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for AMGN moved above the 200-day moving average on November 06, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 05, 2025. You may want to consider a long position or call options on AMGN as a result. In of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on November 05, 2025. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 235 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMGN broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.084) is normal, around the industry mean (9.013). P/E Ratio (26.381) is within average values for comparable stocks, (24.322). Projected Growth (PEG Ratio) (1.072) is also within normal values, averaging (2.089). Dividend Yield (0.028) settles around the average of (0.026) among similar stocks. P/S Ratio (5.136) is also within normal values, averaging (3.702).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
Advertisement